Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suizenji + nanoliposomal irinotecan + fluorouracil
- Development stage
- Unknown
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is a clinical regimen comprising the nanoliposomal formulation of irinotecan (Nal-IRI), the antimetabolite fluorouracil (5-FU), and the cyanobacterium Suizenji-nori (Aphanothece sacrum). Nal-IRI is a topoisomerase I inhibitor that delivers irinotecan via liposomal encapsulation to enhance intratumoral drug concentration and prolong exposure, while fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis. Suizenji-nori, a traditional Japanese food source, is included in this regimen primarily for its high content of sacran, a sulfated polysaccharide with potent anti-inflammatory and water-retention properties. In clinical trials for gemcitabine-refractory pancreatic cancer, Suizenji-nori is administered orally to mitigate chemotherapy-induced gastrointestinal toxicities, specifically diarrhea, by providing mucosal protection and reducing intestinal inflammation.
- Brand names
- Onivyde
- Other names
- Suizenji-nori + Nal-IRI + 5-FUAphanothece sacrum + nanoliposomal irinotecan + 5-fluorouracilSuizenji + Nal-IRI + fluorouracil
02
Targets
DNATS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on suizenji + nanoliposomal irinotecan + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suizenji + nanoliposomal irinotecan + fluorouracil.